LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two Simple Serum Biomarkers Differentiate Lymphoma from Glioma

By LabMedica International staff writers
Posted on 22 Apr 2022
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)

A recent study found that two simple serum biomarkers, absolute lymphocyte count and prognostic nutritional index, which are easily derived from routine pre-treatment blood tests, have fair correlation and acceptable diagnostic accuracy for differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG) in patients with similar morphology on MRI.

A complex series of interactions take place between cancer and inflammation that are reflected by increased release of inflammatory biomarkers into the bloodstream. However, the utility of systemic inflammatory biomarkers as a means for the noninvasive differential diagnosis of PCNSL from HCC is generally lacking.

To repair this lack, investigators at the Homi Bhabha National Institute (Mumbai, India) and their colleagues carried out a study that involved calculating systemic inflammatory indices from pre-treatment complete blood counts and liver function tests and comparing them against histopathology as the reference standard among 42 patients with PCNSL and 16 with HGG.

Results revealed that the area under the receiver operating characteristics curve for absolute lymphocyte count and prognostic nutritional index in the diagnosis of PCNSL was 0.70 and 0.72 respectively, which suggested that these markers yielded fair and acceptable diagnostic accuracy.

The investigators said, "This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging."

The study was published in the April 4, 2022, online edition of the journal CNS Oncology.

Related Links:
Homi Bhabha National Institute 

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gold Member
Hybrid Pipette
SWITCH

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more